Icon

QTERNMET XR (nda210874)- (2.5MG;1GM;EQ 2.5MG BASE,5MG;1GM;EQ 2.5MG BASE,5MG;1GM;EQ 5MG BASE,10MG;1GM;EQ 5MG BASE)

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ASTRAZENECA AB
2.5MG;1GM;EQ 2.5MG BASE,5MG;1GM;EQ 2.5MG BASE,5MG;1GM;EQ 5MG BASE,10MG;1GM;EQ 5MG BASE
No No
2030-Nov-12 Expired
None 2022-May-02
None No
QTERNMET XR is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, a dipeptidyl peptidase-4 (DPP-4) inhibitor and a biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
0 0 0
Total Other Developers None
Drugs with Suitability No
2.5MG;1GM;EQ 2.5MG BASE ** ** - - -
5MG;1GM;EQ 2.5MG BASE ** ** - - -
5MG;1GM;EQ 5MG BASE ** ** - - -
10MG;1GM;EQ 5MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.